Open Your Free Demat Account
Enjoy low brokerage on delivery trades
Source: BSE Last Updated: As per exchange snapshot available at 6:09:49 PM on December 8, 2025
The Corona Remedies Ltd IPO opened on December 8, 2025 and recorded participation across retail, NII, and employee categories on Day 1. The QIB (ex-anchor) segment showed early-phase activity, while the anchor allocation was completed prior to the issue opening.
Monitoring category-wise subscription updates helps understand how different investor groups participate over the subscription period. The figures below reflect the status as per the latest exchange snapshot available at the time of reporting.
As of December 8, 2025 (6:09:49 PM)
Overall subscription: 0.67× (Actual figures may vary with live exchange updates; readers should refer to the BSE/NSE book for the latest numbers.)
Investor Category | Subscription (times) | Shares Offered* | Shares Bid For | Amount (₹ Cr.)* |
Anchor Investors | 1.00 | 18,34,804 | 18,34,804 | 194.856 |
QIB (Ex-Anchor) | 0.00 | 12,21,729 | 2,716 | 0.288 |
Non-Institutional Buyers | 0.84 | 9,16,960 | 7,68,250 | 81.588 |
— bNII (₹10L+) | 0.53 | 6,11,307 | 3,24,646 | 34.477 |
— sNII (<₹10L) | 1.45 | 3,05,653 | 4,43,604 | 47.111 |
Retail Investors | 0.96 | 21,39,573 | 20,44,994 | 217.178 |
Employees | 1.47 | 58,036 | 85,568 | 9.087 |
Total (ex-anchor) | 0.67 | 43,36,298 | 29,01,528 | 308.142 |
Total Applications Received: 1,14,665
*Calculated at the upper end of the price band.
**Anchor portion excluded from the “Total” shares offered.
Total Issue Size: 61,71,101 shares (₹655.37 crore)
Issue Type: Book-built, entirely Offer for Sale (OFS)
Price Band: ₹1008–₹1062 per share
Lot Size: 14 shares
Listing: BSE & NSE
Employee Discount: ₹54 per share
Category | Shares Offered | Amount (₹ Cr.) | Size (%) |
Anchor Investors | 18,34,804 | 194.86 | 29.73% |
QIB (ex-anchor) | 12,21,729 | – | 19.80% |
Overall QIB Quota (incl. Anchor)* | 30,56,533 | – | 49.53% |
NII | 9,16,960 | – | 14.86% |
Retail | 21,39,573 | – | 34.67% |
Employees | 58,036 | – | 0.94% |
Total | 61,71,101 | – | 100% |
*Anchor forms part of the QIB quota under applicable SEBI regulations.
Since the issue comprises an Offer for Sale, proceeds will go to the selling shareholders. The company will not receive funds from this IPO.
Corona Remedies Ltd raised ₹194.86 crore from anchor investors ahead of the IPO.
Particulars | Details |
Anchor Bid Date | December 5, 2025 |
Shares Allotted | 18,34,804 |
Anchor Portion Size | ₹194.86 crore |
Anchor Investor Price | ₹1,062 per share |
Lock-in (30 days) | As per SEBI ICDR norms |
Lock-in (90 days) | As per SEBI ICDR norms |
Note: Actual lock-in distribution follows SEBI’s 30/90-day framework for anchor investors.
Application Type | Lots | Shares | Amount (₹) at Upper Band |
Retail (Min) | 1 | 14 | ₹14,868 |
Retail (Max) | 13 | 182 | ₹1,93,284 |
S-HNI (Min) | 14 | 196 | ₹2,08,152 |
S-HNI (Max) | 67 | 938 | ₹9,96,156 |
B-HNI (Min) | 68 | 952 | ₹10,11,024 |
Event | Date |
IPO Opens | Mon, Dec 8, 2025 |
IPO Closes | Wed, Dec 10, 2025 |
Allotment | Thu, Dec 11, 2025 |
Refund Initiation | Fri, Dec 12, 2025 |
Shares Credit to Demat | Fri, Dec 12, 2025 |
Listing | Mon, Dec 15, 2025 |
UPI Mandate Cut-off | 5 PM on Wed, Dec 10, 2025 |
(Restated consolidated financials as disclosed in offer documents)
Metric (₹ crore) | 30 Jun 2025 | FY25 | FY24 | FY23 |
Assets | 1,012.38 | 929.86 | 830.58 | 595.02 |
Total Income | 348.56 | 1,202.35 | 1,020.93 | 891.10 |
PAT | 46.20 | 149.43 | 90.50 | 84.93 |
EBITDA | 71.80 | 245.91 | 161.19 | 135.03 |
Net Worth | 607.02 | 606.34 | 480.41 | 408.52 |
Total Borrowing | 106.65 | 62.70 | 134.14 | 2.33 |
KPI | Value |
ROE | 27.50% |
ROCE | 41.32% |
Debt/Equity | 0.10 |
RoNW | 24.65% |
PAT Margin | 12.49% |
EBITDA Margin | 20.55% |
P/BV | 10.71 |
Incorporated in 2004, Corona Remedies Ltd operates across therapeutic segments including women’s healthcare, cardio-diabeto, urology, and pain management.
As of June 30, 2025, the company had:
71 brands,
2,671 medical representatives,
Operations across 22 states, and
Two manufacturing facilities in Gujarat with an installed capacity of 1,285.44 million units annually.
The Corona Remedies IPO witnessed participation across retail, NII, and employee categories on Day 1, with anchor activity concluded ahead of the opening. Subscription levels may continue to evolve through the bidding period. Investors should track real-time updates directly from the exchanges for the latest book status.
Interested in more opportunities? Check out our Upcoming IPO section for new listings, and don’t forget to check your IPO allotment status for Corona Remedies.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading